LONDON, UK / ACCESSWIRE / June 13, 2019 / Avacta (AVCT) is developing its Affimer technology for use in therapeutic and diagnostic/reagent applications. The potential of the Affimer technology lies in its formatting capabilities, particularly in the creation of bispecific and TMAC Affimer drug conjugates. Its lead therapeutic asset (AVA004) is a programmed death-ligand 1 (PD-L1)-targeting Affimer for which the company expects to submit an investigational new drug (IND) application in Q420. AVA004 will serve as the first clinical validation of the Affimer technology and will form the base of the clinical development of a PD-L1/LAG-3 bispecific (AVA021) and the first TMAC Affimer drug conjugate (AVA004/100). We value Avacta at Pound 51m or 44p/share.

We value Avacta at Pound 51m or 44p/share based on a sum-of-the-parts valuation built on an rNPV for AVA021, the LG Chem partnership and the peer valuation of the reagents/diagnostic and animal health divisions, in addition to adding in net cash. AVA021 (PD-L1/LAG-3) contributes approximately 50% to our valuation.

Click here to view the full report.

Subscribe to Edison's content to receive reports by email.

All reports published by Edison are free-to-access and available on the website.

About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact Edison:

Dr Daniel Wilkinson, +44 (0)20 3077 5734
Dr Andy Smith, +44 (0)20 3077 5700
[email protected]

Learn more at www.edisongroup.com and connect with Edison on:

LinkedIn: https://www.linkedin.com/company/edison-group-
Twitter: www.twitter.com/Edison_Inv_Res
YouTube: www.youtube.com/edisonitv

SOURCE: Edison Investment Research Limited